Michail_Petrov-96 Atara Biotherapeutics (NASDAQ:ATRA) said the FDA has cleared its application to begin Phase 1 testing of its immunotherapy ATA3219 for the treatment of lupus nephritis. The drug was previously cleared for testing in the treatment of non-Hodgkin’s lymphoma, or NHL. Initial data from the NHL study is expected in the second half of 2024, with data for lupus nephritis expected in the first half of 2025.

Michail\u Petrov-96 Atara Biotherapeutics（纳斯达克：ATRA）表示，FDA已批准其申请，开始对其用于治疗狼疮性肾炎的免疫疗法ATA3219进行第一阶段测试。该药物先前已被批准用于治疗非霍奇金淋巴瘤（NHL）的测试。NHL研究的初步数据预计将在2024年下半年发布，狼疮性肾炎的数据预计将在2025年上半年发布。

More on Atara Biotherapeutics Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma Atara spikes on peer-reviewed Phase 3 data for lead asset Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics .

关于Atara Biotherapeutics的更多信息Atara Biotherapeutics：机会，因为他们出售了他们批准的资产，以获得更长的跑道Baupost集团远离Atara，Veritiv的步骤；由于Clarivate，Jazz Pharma Atara在同行评审的第三阶段数据上取得了领先资产寻求Alpha对Atara Biotherapeutics的定量评级，因此Atara Biotherapeutics的历史收益数据飙升。